Navigation Links
ITRAC on track and bridging gap between academic research and applied discovery

INDIANAPOLIS -- In a novel manner which gives new meaning to the word transformative, researchers from the Indiana University Melvin and Bren Simon Cancer Center are integrating some of the best practices of industry into the strengths of the academic research process to propel the development of innovative cancer treatments from the bench to the bedside.

The IU Simon Cancer Center has initiated the Translational Research Acceleration Collaboration (ITRAC) and is providing rapid response funding and expertise to speed early discoveries to improve patient care, solve perplexing treatment problems, and lead the way to future therapies.

Traditionally, external academic grant funding applications take nine to 12 months from time of submission to funding, if approved. With ITRAC, researchers can receive incremental funding in a fraction of that time.

"ITRAC also helps investigators form research teams and break down silos that are naturally found in any research environment, said Mark Kelley, Ph.D., associate director for basic science research at the IU Simon Cancer Center. "The ITRAC process requires that research teams, including basic and clinical scientists, work together to speed the velocity of the science from the bench to the clinic as well as from the clinic back to the bench. With science becoming ever more complex, the formation of multi-disciplinary teams is the most effective and correct way to undertake complex problems in cancer prevention, detection, treatment and delivery.

This initiative also helps investigators forge new collaborations, share costly resources such as reagents, and develop interactions internally and externally. To date, ITRAC has supported collaborators from the Purdue Cancer Center, the University of Notre Dames Walther Cancer Research Center and the IU Simon Cancer Center.

According to Dr. Kelley, the ITRAC process requires greater accountability by researchers of how funds are used and careful scrutiny of the outcomes. Only research with the greatest patient impact potential is supported.

David Johnson, president and CEO of BioCrossroads, the states initiative to develop the life sciences, said hes not aware of any other university using ITRACs approach to translate discovery into action.

Its revolutionary, Johnson said. Although its in an academic environment, ITRAC tries to bridge the gap between the traditional the pure discovery domain of academic research and the very applied discovery domain of corporate research and development. Its an approach that says were going to borrow some of the project management processes that organize corporate research and focus more specifically on outcomes.

Leaders at the IU Simon Cancer Center approached BioCrossroads for insights into project management practices used in the corporate world.

In addition to grant money, ITRAC helps researchers map out their projects, and it provides expertise to scientists who have made significant discoveries in their labs but arent sure what steps are necessary to turn those discoveries into products that will improve patient care. This decreases the amount of time the scientists have to spend running around trying to find out how to accomplish the next step in their projects.

The program complements a growing emphasis by the National Institutes of Health on accelerating the development and testing processes that basic science laboratory discoveries go through to become new patient treatments. One of the major goals of National Cancer Institute designated centers like the IU Simon Cancer Center is to increase translational initiatives.

IU Simon Cancer Center committees review research projects and identify those with the most potential for clinical applications as well as commercial potential potential that the individual scientists may not even realize is there.

Since its establishment in November 2006, ITRAC has mapped 73 projects, established and/or recommended 50 project collaborations, and identified numerous intellectual property needs.

After little more than a year, an exciting benefit we are seeing is the identification of intellectual property, which, we hope, will continue to grow and dovetail with the growing emphasis in the states life sciences initiative and lead to more biotech startups and licensing opportunities and decrease the brain drain from the state, Kelley said. Whatever it takes to help speed research findings to help cancer patients is what this initiative is all about."


Contact: Cindy Fox Aisen
Indiana University

Related medicine news :

1. Bayer HealthCare Cleared to Acquire Citracal(R)
2. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
3. Mapping tool allows emergency management personnel to visually track resources
4. KLAS Ranks TeleTracking Bed Management Suite No. 1
5. Online Resource Keeps Restaurant Diners on Track After New Years Hype Subsides
6. Breaking Studies at AARC Congress Show Masimo SET and Masimo Rainbow SET to be Accurate, Effective and Uniquely Beneficial in Detecting and Tracking Disease States
7. Tracking Drug Levels Helps Pregnant Women With Epilepsy
8. Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008
9. Design of patient tracking tools may have unintended consequences
10. Scientists Find Way to Track Stem Cells in Brain
11. Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... ... , ... recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: